Variable | NPI (n=74) | NIV (n=76) | p-value |
---|---|---|---|
Age, years | |||
 Median (range) | 35 (21.2–51.8) | 34 (23.8–57.3) | 0.105 |
Sex, n (%) | Â | Â | 0.729 |
 Male | 42 (56.8) | 41 (53.9) |  |
 Female | 32 (43.2) | 35 (46.1) |  |
BMI, kg/m2 | |||
 Median (range) | 25.7 (17.1–41.3) | 25.4 (15.6–43.7) | 0.256 |
ECOG performance status, n (%) | Â | Â | 0.619 |
 0 | 40 (54.1) | 38 (50.0) |  |
 1 | 34 (45.9) | 38 (50.0) |  |
Sarcoma typesa, n (%) | Â | Â | 0.764 |
 Non-uterine leiomyosarcoma | 43 (58.1) | 40 (52.6) |  |
 Liposarcomab | 20 (27.0) | 22 (28.9) |  |
 Synovial sarcoma | 11 (14.9) | 14 (18.4) |  |
Three major types of liposarcoma | Â | Â | 0.078 |
 Atypical lipoma | 9 (12.1) | 11 (14.5) |  |
 Myxoid liposarcoma | 10 (13.5) | 9 (11.8) |  |
 Pleomorphic liposarcoma | 1 (1.4) | 2 (2.6) |  |
Histological grade, n (%) | Â | Â | 0.504 |
 G1 (well differentiated) | 31 (41.9) | 37 (48.7) |  |
 G2 (moderately differentiated) | 27 (36.5) | 21 (27.6) |  |
 G3 (poorly differentiated) | 16 (21.6) | 18 (23.7) |  |
TMBc status (per Mb), n (%) | Â | Â | 0.716 |
 TMB-High (> 5) | 45 (60.8) | 44 (57.9) |  |
 TMB-Low (0–5) | 29 (39.2) | 32 (42.1) |  |
Duration of treatment (months) | Â | Â | Â |
 Median (range) | 3 (1.5–4.4) | 3 (1.6–4.7) | 0.317 |
Number of metastatic sites, n (%) | Â | Â | 0.583 |
 3 | 12 (16.2) | 10 (13.2) |  |
 > 3 | 51 (68.9) | 58 (76.3) |  |
 Unknown | 11(14.9) | 8 (10.5) |  |